Literature DB >> 22251182

Average cost-effectiveness ratio with censored data.

Heejung Bang1, Hongwei Zhao.   

Abstract

In cost-effectiveness analysis, interest could lie foremost in the incremental cost-effectiveness ratio (ICER), which is the ratio of the incremental cost to the incremental benefit of two competing interventions. The average cost-effectiveness ratio (ACER) is the ratio of the cost to benefit of an intervention without reference to a comparator. A vast literature is available for statistical inference of the ICERs, but limited methods have been developed for the ACERs, particularly in the presence of censoring. Censoring is a common feature in prospective studies, and valid analyses should properly adjust for censoring in cost as well as in effectiveness. In this article, we propose statistical methods for constructing a confidence interval for the ACER from censored data. Different methods-Fieller, Taylor, bootstrap-are proposed, and through simulation studies and data analysis, we address the performance characteristics of these methods.

Entities:  

Mesh:

Year:  2012        PMID: 22251182      PMCID: PMC3307793          DOI: 10.1080/10543406.2010.544437

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  30 in total

1.  On estimating medical cost and incremental cost-effectiveness ratios with censored data.

Authors:  H Zhao; L Tian
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  On estimators of medical costs with censored data.

Authors:  Anthony O'Hagan; John W Stevens
Journal:  J Health Econ       Date:  2004-05       Impact factor: 3.883

3.  Medical cost analysis: application to colorectal cancer data from the SEER Medicare database.

Authors:  Heejung Bang
Journal:  Contemp Clin Trials       Date:  2005-10       Impact factor: 2.226

4.  Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial.

Authors:  M A Chaudhary; S C Stearns
Journal:  Stat Med       Date:  1996-07-15       Impact factor: 2.373

5.  The usefulness of average cost-effective ratios.

Authors:  E M Laska; M Meisner; C Siegel
Journal:  Health Econ       Date:  1997 Sep-Oct       Impact factor: 3.046

6.  Statistical inference for cost-effectiveness ratios.

Authors:  E M Laska; M Meisner; C Siegel
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

Review 7.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

Authors:  A H Briggs; D E Wonderling; C Z Mooney
Journal:  Health Econ       Date:  1997 Jul-Aug       Impact factor: 3.046

8.  The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial.

Authors:  A I Mushlin; W J Hall; J Zwanziger; E Gajary; M Andrews; R Marron; K H Zou; A J Moss
Journal:  Circulation       Date:  1998-06-02       Impact factor: 29.690

9.  Cost analysis with censored data.

Authors:  Yijian Huang
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

10.  Confidence intervals for cost-effectiveness ratios.

Authors:  J Gardiner; A Hogan; M Holmes-Rovner; D Rovner; L Griffith; J Kupersmith
Journal:  Med Decis Making       Date:  1995 Jul-Sep       Impact factor: 2.583

View more
  10 in total

Review 1.  Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy.

Authors:  Ethna McFerran; James F O'Mahony; Richard Fallis; Duncan McVicar; Ann G Zauber; Frank Kee
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

2.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

3.  Over-the-scope clips are cost-effective in recurrent peptic ulcer bleeding.

Authors:  Armin Kuellmer; Juliane Behn; Benjamin Meier; Andreas Wannhoff; Dominik Bettinger; Robert Thimme; Karel Caca; Arthur Schmidt
Journal:  United European Gastroenterol J       Date:  2019-09-25       Impact factor: 4.623

4.  Median-based incremental cost-effectiveness ratios with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2015-05-26       Impact factor: 1.051

5.  Cost-Effectiveness of Presbyopia Correction Among Seven Strategies of Bilateral Cataract Surgery Based on a Prospective Single-Blind Two-Center Trial in China.

Authors:  Qianqian Lan; Yiyun Liu; Fan Xu; Min Li; Yaxin Li; Tingting Yang; Tong Sun; Gang Yao; Baikai Ma; Liyuan Tao; Xin Xiao; Xing Lin Feng; Siming Zeng; Hong Qi
Journal:  Ophthalmol Ther       Date:  2022-09-07

6.  The impact of preoperative patient characteristics on the cost-effectiveness of total hip replacement: a cohort study.

Authors:  Matthias Vogl; Rainer Wilkesmann; Christian Lausmann; Werner Plötz
Journal:  BMC Health Serv Res       Date:  2014-08-15       Impact factor: 2.655

7.  A comparative study of aceclofenac versus etoricoxib in the management of acute low back pain in a tertiary care hospital.

Authors:  Hema Jagannathan; Amulya Thota; Ashok Kumar B Kumarappa; Githa Kishore
Journal:  J Drug Assess       Date:  2020-03-31

8.  The Cost-Effectiveness Analysis of the Productivity Measurement and Enhancement System Intervention to Reduce Employee Work-Related Stress and Enhance Work Performance.

Authors:  Irene Jensen; Zana Arapovic-Johansson; Emmanuel Aboagye
Journal:  Int J Environ Res Public Health       Date:  2022-02-19       Impact factor: 3.390

9.  Endoscopic full-thickness resection and its treatment alternatives in difficult-to-treat lesions of the lower gastrointestinal tract: a cost-effectiveness analysis.

Authors:  Armin Kuellmer; Juliane Behn; Torsten Beyna; Brigitte Schumacher; Alexander Meining; Helmut Messmann; Horst Neuhaus; David Albers; Michael Birk; Andreas Probst; Martin Faehndrich; Thomas Frieling; Martin Goetz; Robert Thimme; Karel Caca; Arthur Schmidt
Journal:  BMJ Open Gastroenterol       Date:  2020-08

10.  A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK®) lowering cardiovascular disease risk.

Authors:  Andrea Manfrin; Valentina Trimarco; Maria Virginia Manzi; Francesco Rozza; Raffaele Izzo
Journal:  Clinicoecon Outcomes Res       Date:  2018-10-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.